Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Gesine Bug, MD, Carsten Müller-Tidow, MD, Richard F Schlenk, MD, Alwin Krämer, MD, Michael Lübbert, MD, PhD, Utz Krug, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Pilar Garin-Chesa, MD, PhD, Oliver G Ottmann, MD, Hartmut Döhner, MD

Blood (2011) 118 (21): 1549.

https://doi.org/10.1182/blood.V118.21.1549.1549

Published: 2011

Journal Articles

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Steffen Koschmieder, MD, Mirle Schemionek, PhD, Christian Elling, PhD, Utz Krug, MD, Torsten Kessler, MD, Wolfgang E. Berdel, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 5153.

https://doi.org/10.1182/blood.V118.21.5153.5153

Published: 2011

Journal Articles

Identification of the PML-RARα Associated DNA Methylome Using Reduced Representation Bisulfite Sequencing in Primary Patient Samples

Christian Rohde, PhD, Till Schoofs, Katja Hebestreit, Hans-Ulrich Klein, PhD, Anika Witten, PhD, Monika Stoll, PhD, Eva Lengfelder, MD, Wolf-Karsten Hofmann, MD, Peter Schlenke, PhD, Stefanie Göllner, PhD, Thomas Büchner, MD, Maria Cristina Sauerland, Steffen Koschmieder, MD, Wolfgang E. Berdel, Martin Dugas, MD, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 2436.

https://doi.org/10.1182/blood.V118.21.2436.2436

Published: 2011

Journal Articles

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Blood (2011) 118 (21): 255.

https://doi.org/10.1182/blood.V118.21.255.255

Published: 2011

Journal Articles

Loss of EZH2 and Aberrant DNA Methylation Account for PKC412 Drug Resistance in the FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cell Line MV4-11,

Stefanie Göllner, PhD, Tino Schenk, PhD, Christian Rohde, PhD, Arthur Zelent, PhD, Friedrich Stölzel, MD, Christian Thiede, MD, Wolfgang E. Berdel, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 3468.

https://doi.org/10.1182/blood.V118.21.3468.3468

Published: 2011

Journal Articles

A Distinct DNA Methylation Pattern Characterizes Childhood Acute Lymphoblastic Leukemia and Separates Patients Into Prognostic Groups,

Stefanie Göllner, PhD, Anika Witten, PhD, Monika Stoll, PhD, Wolfgang E. Berdel, Martin Schrappe, MD, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 3568.

https://doi.org/10.1182/blood.V118.21.3568.3568

Published: 2011

Journal Articles

DNMT3B Expression Delays Leukemogenesis,

Petra Tschanter, MD, Isabell Schulze, Nicole Bäumer, Beate Surmann, Konstantin Agelopoulos, Utz Krug, MD, Wolfgang E. Berdel, MD, Heinz Linhart, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 3446.

https://doi.org/10.1182/blood.V118.21.3446.3446

Published: 2011

Journal Articles

Histone H3 Methylation Mediates All- Trans -Retinoic Acid Responsiveness in Acute Myeloid Leukemia

Tino Schenk, PhD, Stefanie Göllner, PhD, Weihsu Claire Chen, PhD, Louise Howell, BSc, Liqing Jin, MD, Katja Hebestreit, Hans-Ulrich Klein, PhD, Alan K Burnett, MD, Ken I. Mills, PhD, FRCPath, Laurence Marton, MD, Robert Casero, Jr., PhD, Patrick Woster, PhD, Martin Dugas, MD, Jean C.Y. Wang, MD, PhD, John E. Dick, PhD, Carsten Müller-Tidow, MD, Kevin Petrie, PhD, Arthur Zelent, PhD

Blood (2011) 118 (21): 224.

https://doi.org/10.1182/blood.V118.21.224.224

Published: 2011

Journal Articles

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD, Richard F. Schlenk, MD, PhD, Carsten Müller-Tidow, MD, PhD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, PhD, Frank Fleischer, Tillmann Taube, MD, Oliver G. Ottmann, MD, PhD, Hartmut Doehner, MD, PhD

Blood (2010) 116 (21): 3316.

https://doi.org/10.1182/blood.V116.21.3316.3316

Published: 2010

Journal Articles

Genome Wide Screening Reveals Distinct Signaling Pathways of the ETS Transcription Factor ERG In Primary Acute Leukemia Blasts

Juliane Bock, PhD, Liliana H. Mochmann, Stefanie Göllner, PhD, Eckhard Thiel, Prof., Dr., Dr., h.c., Carsten Müller-Tidow, MD, Claudia Baldus, PhD

Blood (2010) 116 (21): 4184.

https://doi.org/10.1182/blood.V116.21.4184.4184

Published: 2010

Journal Articles

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Utz O Krug, MD, Anja Koschmieder, Joachim Gerss, PhD, Hubert Serve, MD, Björn Steffen, MD, Gesine Bug, MD, Markus Schaich, MD, Christian Brandts, MD, Christoph Röllig, MD, Gerhard Ehninger, MD, Ulrich Duehrsen, MD, Richard Noppeney, MD, Wolfgang E. Berdel, MD, Steffen Koschmieder, MD, Carsten Müller-Tidow, MD

Blood (2010) 116 (21): 2180.

https://doi.org/10.1182/blood.V116.21.2180.2180

Published: 2010

Journal Articles

Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis

Maya koren-Michowitz, MD, Carsten Müller-Tidow, MD, Aiko Matsubara, MS, Stefanie Göllner, PhD, Wolfgang E. Berdel, Arnon Nagler, M.D., Seishi Ogawa, MD, PhD, H. Phillip Koeffler, MD

Blood (2010) 116 (21): 2479.

https://doi.org/10.1182/blood.V116.21.2479.2479

Published: 2010

Journal Articles

A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.

Utz O. Krug, MD, Achim Heinecke, PhD, Anja Koschmieder, MD, Matthias Stelljes, MD, Maria Cristina Sauerland, PhD, Wolfgang E Berdel, MD, Bernhard J Woermann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD, Carsten Müller-Tidow, MD

Blood (2009) 114 (22): 327.

https://doi.org/10.1182/blood.V114.22.327.327

Published: 2009

Journal Articles

Mtss1 Suppresses BCR-ABL Induced Cell Migration and Is Downregulated in CML Stem Cells.

Mirle Schemionek, Shuchi Agrawal, PhD, Martin Stehling, PhD, Daniel G. Tenen, MD, Ashley Hamilton, Tessa Holyoake, MD, PhD, Ulrich Steidl, MD, PhD, Wolfgang E. Berdel, MD, Albrecht Schwab, MD, Carsten Müller-Tidow, MD, Steffen Koschmieder, MD

Blood (2008) 112 (11): 1077.

https://doi.org/10.1182/blood.V112.11.1077.1077

Published: 2008

Journal Articles

Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients

Kang-Hun Lee, MD, Richard F. Schlenk, MD, Gesine Bug, MD, Carsten Müller-Tidow, MD, Ralph M. Waesch, MD, David Nachbaur, MD, Peter Valent, MD, Gerd Munzert, MD, Frank Fleischer, PhD, Hartmut Dohner, MD, PhD, Pilar Garin-Chesa, PhD

Blood (2008) 112 (11): 2641.

https://doi.org/10.1182/blood.V112.11.2641.2641

Published: 2008

Journal Articles

Reversible Transplantable Chronic Phase CML-Like Disease in SCLtTA/BCR-ABL Transgenic Mice.

Mirle Schemionek, Jörg Stypmann, MD, Sven Hermann, MD, Christian Elling, Nicole Bäumer, PhD, Tilmann Spieker, MD, Joachim R. Göthert, MD, Martin Stehling, PhD, Claudia S. Huettner, PhD, Michael Schäfers, MD, Daniel G. Tenen, MD, Wolfgang E. Berdel, MD, Tessa L. Holyoake, MD, Carsten Müller-Tidow, MD, Hubert Serve, MD, Steffen Koschmieder, MD

Blood (2007) 110 (11): 1002.

https://doi.org/10.1182/blood.V110.11.1002.1002

Published: 2007

Journal Articles

CDDO Increases Translation of CCAAT Enhancer Binding Protein alpha To Induce Granulocytic Differentiation.

Steffen Koschmieder, MD, Francesco D′Alo′, MD, Hanna Radomska, PhD, Susumu Kobayashi, MD, PhD, Elena Levantini, PhD, Nanjoo Suh, PhD, Michael B. Sporn, MD, Annalisa Di Ruscio, MD, Maria Teresa Voso, MD, Wolfgang E. Berdel, MD, Carsten Müller-Tidow, MD, Hubert Serve, MD, Daniel G. Tenen, MD

Blood (2005) 106 (11): 2458.

https://doi.org/10.1182/blood.V106.11.2458.2458

Published: 2005

NARROW

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Identification of the PML-RARα Associated DNA Methylome Using Reduced Representation Bisulfite Sequencing in Primary Patient Samples

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Loss of EZH2 and Aberrant DNA Methylation Account for PKC412 Drug Resistance in the FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cell Line MV4-11,

A Distinct DNA Methylation Pattern Characterizes Childhood Acute Lymphoblastic Leukemia and Separates Patients Into Prognostic Groups,

DNMT3B Expression Delays Leukemogenesis,

Histone H3 Methylation Mediates All- Trans -Retinoic Acid Responsiveness in Acute Myeloid Leukemia

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Genome Wide Screening Reveals Distinct Signaling Pathways of the ETS Transcription Factor ERG In Primary Acute Leukemia Blasts

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis

A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.

Mtss1 Suppresses BCR-ABL Induced Cell Migration and Is Downregulated in CML Stem Cells.

Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients

Reversible Transplantable Chronic Phase CML-Like Disease in SCLtTA/BCR-ABL Transgenic Mice.

CDDO Increases Translation of CCAAT Enhancer Binding Protein alpha To Induce Granulocytic Differentiation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only